期 |
栏目 |
标题 |
文件 |
卷 92, 编号 2 (2020) |
Editorial |
Systemic manifestations of inflammatory bowel diseases |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 92, 编号 2 (2020) |
Consensuns |
Multidisciplinary treatment of the patient with a severe irritable bowel syndrome |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 92, 编号 2 (2020) |
Original articles |
Bile acids are a risk factor for colorectal cancer |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 92, 编号 2 (2020) |
Original articles |
Pharmacological and clinical feature of rebamipide: new therapeutic targets |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 92, 编号 12 (2020) |
Articles |
Chronic intestinal pseudo-obstruction |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 92, 编号 12 (2020) |
Articles |
Resected bowel syndrome: clinical course and treatment options |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 93, 编号 2 (2021) |
Editorial |
Enteropathy with impaired membrane digestion and the prospects for cytoprotective therapy |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 93, 编号 2 (2021) |
Original articles |
Screening for celiac disease among patients of the gastroenterological profile |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 93, 编号 2 (2021) |
Original articles |
Loss of response and frequency of adverse events in patients with ulcerative colitis and Crohn’s disease when switching from the original infliximab to its biosimilars |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 93, 编号 2 (2021) |
Reviews |
Clinical value of antibodies in inflammatory bowel diseases |
![PDF](/img/labels/pdf.png) (Rus)
|
卷 93, 编号 2 (2021) |
History of medicine |
Historical milestones in the knowledge of celiac disease: on the 80th anniversary of the discovery of W.-K. Dike of the аgluten diet |
![PDF](/img/labels/pdf.png) (Rus)
|